Therapeutic properties of mesenchymal stem cells for autism spectrum disorders

Benjamin Gesundheit, Paul Ashwood, Armand Keating, David Naor, Michal Melamed, Joshua P. Rosenzweig

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Recent studies of autism spectrum disorders (ASD) highlight hyperactivity of the immune system, irregular neuronal growth and increased size and number of microglia. Though the small sample size in many of these studies limits extrapolation to all individuals with ASD, there is mounting evidence of both immune and nervous system related pathogenesis in at least a subset of patients with ASD. Given the disturbing rise in incidence rates for ASD, and the fact that no pharmacological therapy for ASD has been approved by the Food and Drug Administration (FDA), there is an urgent need for new therapeutic options. Research in the therapeutic effects of mesenchymal stem cells (MSC) for other immunological and neurological conditions has shown promising results in preclinical and even clinical studies. MSC have demonstrated the ability to suppress the immune system and to promote neurogenesis with a promising safety profile. The working hypothesis of this paper is that the potentially synergistic ability of MSC to modulate a hyperactive immune system and its ability to promote neurogenesis make it an attractive potential therapeutic option specifically for ASD. Theoretical mechanisms of action will be suggested, but further research is necessary to support these hypothetical pathways. The choice of tissue source, type of cell, and most appropriate ages for therapeutic intervention remain open questions for further consideration. Concern over poor regulatory control of stem cell studies or treatment, and the unique ethical challenges that each child with ASD presents, demands that future research be conducted with particular caution before widespread use of the proposed therapeutic intervention is implemented.

Original languageEnglish (US)
Pages (from-to)169-177
Number of pages9
JournalMedical Hypotheses
Volume84
Issue number3
DOIs
StatePublished - Mar 1 2015

Fingerprint

Mesenchymal Stromal Cells
Aptitude
Immune System
Neurogenesis
Therapeutic Uses
Therapeutics
Microglia
United States Food and Drug Administration
Autism Spectrum Disorder
Research
Sample Size
Nervous System
Stem Cells
Pharmacology
Safety
Incidence
Growth

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Therapeutic properties of mesenchymal stem cells for autism spectrum disorders. / Gesundheit, Benjamin; Ashwood, Paul; Keating, Armand; Naor, David; Melamed, Michal; Rosenzweig, Joshua P.

In: Medical Hypotheses, Vol. 84, No. 3, 01.03.2015, p. 169-177.

Research output: Contribution to journalArticle

Gesundheit, B, Ashwood, P, Keating, A, Naor, D, Melamed, M & Rosenzweig, JP 2015, 'Therapeutic properties of mesenchymal stem cells for autism spectrum disorders', Medical Hypotheses, vol. 84, no. 3, pp. 169-177. https://doi.org/10.1016/j.mehy.2014.12.016
Gesundheit, Benjamin ; Ashwood, Paul ; Keating, Armand ; Naor, David ; Melamed, Michal ; Rosenzweig, Joshua P. / Therapeutic properties of mesenchymal stem cells for autism spectrum disorders. In: Medical Hypotheses. 2015 ; Vol. 84, No. 3. pp. 169-177.
@article{89ee686b1c5a441185f08c5165e3b375,
title = "Therapeutic properties of mesenchymal stem cells for autism spectrum disorders",
abstract = "Recent studies of autism spectrum disorders (ASD) highlight hyperactivity of the immune system, irregular neuronal growth and increased size and number of microglia. Though the small sample size in many of these studies limits extrapolation to all individuals with ASD, there is mounting evidence of both immune and nervous system related pathogenesis in at least a subset of patients with ASD. Given the disturbing rise in incidence rates for ASD, and the fact that no pharmacological therapy for ASD has been approved by the Food and Drug Administration (FDA), there is an urgent need for new therapeutic options. Research in the therapeutic effects of mesenchymal stem cells (MSC) for other immunological and neurological conditions has shown promising results in preclinical and even clinical studies. MSC have demonstrated the ability to suppress the immune system and to promote neurogenesis with a promising safety profile. The working hypothesis of this paper is that the potentially synergistic ability of MSC to modulate a hyperactive immune system and its ability to promote neurogenesis make it an attractive potential therapeutic option specifically for ASD. Theoretical mechanisms of action will be suggested, but further research is necessary to support these hypothetical pathways. The choice of tissue source, type of cell, and most appropriate ages for therapeutic intervention remain open questions for further consideration. Concern over poor regulatory control of stem cell studies or treatment, and the unique ethical challenges that each child with ASD presents, demands that future research be conducted with particular caution before widespread use of the proposed therapeutic intervention is implemented.",
author = "Benjamin Gesundheit and Paul Ashwood and Armand Keating and David Naor and Michal Melamed and Rosenzweig, {Joshua P.}",
year = "2015",
month = "3",
day = "1",
doi = "10.1016/j.mehy.2014.12.016",
language = "English (US)",
volume = "84",
pages = "169--177",
journal = "Medical Hypotheses",
issn = "0306-9877",
publisher = "Churchill Livingstone",
number = "3",

}

TY - JOUR

T1 - Therapeutic properties of mesenchymal stem cells for autism spectrum disorders

AU - Gesundheit, Benjamin

AU - Ashwood, Paul

AU - Keating, Armand

AU - Naor, David

AU - Melamed, Michal

AU - Rosenzweig, Joshua P.

PY - 2015/3/1

Y1 - 2015/3/1

N2 - Recent studies of autism spectrum disorders (ASD) highlight hyperactivity of the immune system, irregular neuronal growth and increased size and number of microglia. Though the small sample size in many of these studies limits extrapolation to all individuals with ASD, there is mounting evidence of both immune and nervous system related pathogenesis in at least a subset of patients with ASD. Given the disturbing rise in incidence rates for ASD, and the fact that no pharmacological therapy for ASD has been approved by the Food and Drug Administration (FDA), there is an urgent need for new therapeutic options. Research in the therapeutic effects of mesenchymal stem cells (MSC) for other immunological and neurological conditions has shown promising results in preclinical and even clinical studies. MSC have demonstrated the ability to suppress the immune system and to promote neurogenesis with a promising safety profile. The working hypothesis of this paper is that the potentially synergistic ability of MSC to modulate a hyperactive immune system and its ability to promote neurogenesis make it an attractive potential therapeutic option specifically for ASD. Theoretical mechanisms of action will be suggested, but further research is necessary to support these hypothetical pathways. The choice of tissue source, type of cell, and most appropriate ages for therapeutic intervention remain open questions for further consideration. Concern over poor regulatory control of stem cell studies or treatment, and the unique ethical challenges that each child with ASD presents, demands that future research be conducted with particular caution before widespread use of the proposed therapeutic intervention is implemented.

AB - Recent studies of autism spectrum disorders (ASD) highlight hyperactivity of the immune system, irregular neuronal growth and increased size and number of microglia. Though the small sample size in many of these studies limits extrapolation to all individuals with ASD, there is mounting evidence of both immune and nervous system related pathogenesis in at least a subset of patients with ASD. Given the disturbing rise in incidence rates for ASD, and the fact that no pharmacological therapy for ASD has been approved by the Food and Drug Administration (FDA), there is an urgent need for new therapeutic options. Research in the therapeutic effects of mesenchymal stem cells (MSC) for other immunological and neurological conditions has shown promising results in preclinical and even clinical studies. MSC have demonstrated the ability to suppress the immune system and to promote neurogenesis with a promising safety profile. The working hypothesis of this paper is that the potentially synergistic ability of MSC to modulate a hyperactive immune system and its ability to promote neurogenesis make it an attractive potential therapeutic option specifically for ASD. Theoretical mechanisms of action will be suggested, but further research is necessary to support these hypothetical pathways. The choice of tissue source, type of cell, and most appropriate ages for therapeutic intervention remain open questions for further consideration. Concern over poor regulatory control of stem cell studies or treatment, and the unique ethical challenges that each child with ASD presents, demands that future research be conducted with particular caution before widespread use of the proposed therapeutic intervention is implemented.

UR - http://www.scopus.com/inward/record.url?scp=84925365493&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925365493&partnerID=8YFLogxK

U2 - 10.1016/j.mehy.2014.12.016

DO - 10.1016/j.mehy.2014.12.016

M3 - Article

C2 - 25592283

AN - SCOPUS:84925365493

VL - 84

SP - 169

EP - 177

JO - Medical Hypotheses

JF - Medical Hypotheses

SN - 0306-9877

IS - 3

ER -